The 'complexities' of life and death: Death receptor signalling platforms

Experimental Cell Research

Volumn 318, Issue 11, 2012, Pages 1269-1277

  Dickens, Laura S ^a   Powley, Ian R ^a   Hughes, Michelle A ^a   MacFarlane, Marion ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Apoptosis; Caspase 8; CFLIP; DISC; FADD; Necroptosis; RIPK

Indexed keywords

APOPTOSOME; CASPASE 8; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DEATH RECEPTOR; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLICE INHIBITORY PROTEIN; I KAPPA B KINASE GAMMA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; BACTERIAL INFECTION; CANCER RISK; CELL DEATH; CELL SURVIVAL; COMPLEX FORMATION; CYTOMEGALOVIRUS INFECTION; ENZYME ACTIVATION; GENE MUTATION; HUMAN; IMMUNITY; INFLAMMATION; NECROPTOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VIRUS INFECTION;

EID: 84861653411     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.04.005     Document Type: Review

References (73)

1. Degterev A., Huang Z., Boyce M., Li Y., Jagtap P., Mizushima N., Cuny G.D., Mitchison T.J., Moskowitz M.A., Yuan J. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat. Chem. Biol. 2005, 1:112-119.
2. Wagner K.W., Punnoose E.A., Januario T., Lawrence D.A., Pitti R.M., Lancaster K., Lee D., von Goetz M., Yee S.F., Totpal K., Huw L., Katta V., Cavet G., Hymowitz S.G., Amler L., Ashkenazi A. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 2007, 13:1070-1077.
3. Leon-Bollotte L., Lamrani M., Plenchette-Colas S., Jeannin J., Bettaieb A. Post-translational regulation of Fas/CD95 in cell death and survival: role of nitric oxide. Forum on Immunopathological Diseases and Therapeutics 2010, 1:297.
4. Wajant H., Moosmayer D., Wuest T., Bartke T., Gerlach E., Schonherr U., Peters N., Scheurich P., Pfizenmaier K. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 2001, 20:4101-4106.
5. Natoni A., MacFarlane M., Inoue S., Walewska R., Majid A., Knee D., Stover D.R., Dyer M.J., Cohen G.M. TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. Br. J. Haematol. 2007, 139:568-577.
6. Kischkel F.C., Lawrence D.A., Chuntharapai A., Schow P., Kim K.J., Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000, 12:611-620.
7. Schneider P., Thome M., Burns K., Bodmer J.L., Hofmann K., Kataoka T., Holler N., Tschopp J. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 1997, 7:831-836.
8. Kelley R.F., Totpal K., Lindstrom S.H., Mathieu M., Billeci K., Deforge L., Pai R., Hymowitz S.G., Ashkenazi A. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J. Biol. Chem. 2005, 280:2205-2212.
9. MacFarlane M., Kohlhaas S.L., Sutcliffe M.J., Dyer M.J., Cohen G.M. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res. 2005, 65:11265-11270.
10. Aza-Blanc P., Cooper C.L., Wagner K., Batalov S., Deveraux Q.L., Cooke M.P. Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. Mol. Cell 2003, 12:627-637.
11. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001, 104:487-501.
12. Bodmer J.L., Schneider P., Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem. Sci. 2002, 27:19-26.
13. Esposito D., Sankar A., Morgner N., Robinson C.V., Rittinger K., Driscoll P.C. Solution NMR investigation of the CD95/FADD homotypic death domain complex suggests lack of engagement of the CD95 C terminus. Structure 2010, 18:1378-1390.
14. Wang L., Yang J.K., Kabaleeswaran V., Rice A.J., Cruz A.C., Park A.Y., Yin Q., Damko E., Jang S.B., Raunser S., Robinson C.V., Siegel R.M., Walz T., Wu H. The Fas-FADD death domain complex structure reveals the basis of DISC assembly and disease mutations. Nat. Struct. Mol. Biol. 2010, 17:1324-1329.
15. Scott F.L., Stec B., Pop C., Dobaczewska M.K., Lee J.J., Monosov E., Robinson H., Salvesen G.S., Schwarzenbacher R., Riedl S.J. The Fas-FADD death domain complex structure unravels signalling by receptor clustering. Nature 2009, 457:1019-1022.
16. Sandu C., Morisawa G., Wegorzewska I., Huang T., Arechiga A.F., Hill J.M., Kim T., Walsh C.M., Werner M.H. FADD self-association is required for stable interaction with an activated death receptor. Cell Death Differ. 2006, 13:2052-2061.
17. Yang J.K., Wang L., Zheng L., Wan F., Ahmed M., Lenardo M.J., Wu H. Crystal structure of MC159 reveals molecular mechanism of DISC assembly and FLIP inhibition. Mol. Cell 2005, 20:939-949.
18. Carrington P.E., Sandu C., Wei Y., Hill J.M., Morisawa G., Huang T., Gavathiotis E., Wei Y., Werner M.H. The structure of FADD and its mode of interaction with procaspase-8. Mol. Cell 2006, 22:599-610.
19. Tsukumo S.I., Yonehara S. Requirement of cooperative functions of two repeated death effector domains in caspase-8 and in MC159 for induction and inhibition of apoptosis, respectively. Genes Cells 1999, 4:541-549.
20. Varfolomeev E., Maecker H., Sharp D., Lawrence D., Renz M., Vucic D., Ashkenazi A. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J. Biol. Chem. 2005, 280:40599-40608.
21. Lavrik I.N., Mock T., Golks A., Hoffmann J.C., Baumann S., Krammer P.H. CD95 stimulation results in the formation of a novel death effector domain protein-containing complex. J. Biol. Chem. 2008, 283:26401-26408.
22. Lobito A.A., Gabriel T.L., Medema J.P., Kimberley F.C. Disease causing mutations in the TNF and TNFR superfamilies: focus on molecular mechanisms driving disease. Trends Mol. Med. 2011, 17:494-505.
23. Wajant H., Pfizenmaier K., Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003, 10:45-65.
24. Micheau O., Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003, 114:181-190.
25. Harper N., Hughes M., MacFarlane M., Cohen G.M. Fas-associated death domain protein and caspase-8 are not recruited to the tumor necrosis factor receptor 1 signaling complex during tumor necrosis factor-induced apoptosis. J. Biol. Chem. 2003, 278:25534-25541.
26. Gyrd-Hansen M., Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat. Rev. Cancer 2010, 10:561-574.
27. Ramakrishnan P., Baltimore D. Sam68 is required for both NF-kappaB activation and apoptosis signaling by the TNF receptor. Mol. Cell 2011, 43:167-179.
28. Vucic D., Dixit V.M., Wertz I.E. Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat. Rev. Mol. Cell Biol. 2011, 12:439-452.
29. Wang L., Du F., Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008, 133:693-703.
30. Schneider-Brachert W., Tchikov V., Neumeyer J., Jakob M., Winoto-Morbach S., Held-Feindt J., Heinrich M., Merkel O., Ehrenschwender M., Adam D., Mentlein R., Kabelitz D., Schutze S. Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 2004, 21:415-428.
31. Boatright K.M., Renatus M., Scott F.L., Sperandio S., Shin H., Pedersen I.M., Ricci J.E., Edris W.A., Sutherlin D.P., Green D.R., Salvesen G.S. A unified model for apical caspase activation. Mol. Cell 2003, 11:529-541.
32. Donepudi M., Mac Sweeney A., Briand C., Grutter M.G. Insights into the regulatory mechanism for caspase-8 activation. Mol. Cell 2003, 11:543-549.
33. Keller N., Mares J., Zerbe O., Grutter M.G. Structural and biochemical studies on procaspase-8: new insights on initiator caspase activation. Structure 2009, 17:438-448.
34. Kang T.B., Oh G.S., Scandella E., Bolinger B., Ludewig B., Kovalenko A., Wallach D. Mutation of a self-processing site in caspase-8 compromises its apoptotic but not its nonapoptotic functions in bacterial artificial chromosome-transgenic mice. J. Immunol. 2008, 181:2522-2532.
35. Hughes M.A., Harper N., Butterworth M., Cain K., Cohen G.M., MacFarlane M. Reconstitution of the death-inducing signaling complex reveals a substrate switch that determines CD95-mediated death or survival. Mol. Cell 2009, 35:265-279.
36. Oberst A., Pop C., Tremblay A.G., Blais V., Denault J.B., Salvesen G.S., Green D.R. Inducible dimerization and inducible cleavage reveal a requirement for both processes in caspase-8 activation. J. Biol. Chem. 2010, 285:16632-16642.
37. Cursi S., Rufini A., Stagni V., Condo I., Matafora V., Bachi A., Bonifazi A.P., Coppola L., Superti-Furga G., Testi R., Barila D. Src kinase phosphorylates caspase-8 on Tyr380: a novel mechanism of apoptosis suppression. EMBO J. 2006, 25:1895-1905.
38. Jin Z., Li Y., Pitti R., Lawrence D., Pham V.C., Lill J.R., Ashkenazi A. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 2009, 137:721-735.
39. Tschopp J., Irmler M., Thome M. Inhibition of Fas death signals by FLIPs. Curr. Opin. Immunol. 1998, 10:552-558.
40. Krueger A., Schmitz I., Baumann S., Krammer P.H., Kirchhoff S. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J. Biol. Chem. 2001, 276:20633-20640.
41. Golks A., Brenner D., Fritsch C., Krammer P.H., Lavrik I.N. c-FLIPR, a new regulator of death receptor-induced apoptosis. J. Biol. Chem. 2005, 280:14507-14513.
42. Fricker N., Beaudouin J., Richter P., Eils R., Krammer P.H., Lavrik I.N. Model-based dissection of CD95 signaling dynamics reveals both a pro- and anti-apoptotic role of c-FLIPL. J. Cell Biol. 2010, 190:377-389.
43. Chang D.W., Xing Z., Pan Y., Algeciras-Schimnich A., Barnhart B.C., Yaish-Ohad S., Peter M.E., Yang X. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J. 2002, 21:3704-3714.
44. Scaffidi C., Schmitz I., Krammer P.H., Peter M.E. The role of c-FLIP in modulation of CD95-induced apoptosis. J. Biol. Chem. 1999, 274:1541-1548.
45. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., Bodmer J.L., Schroter M., Burns K., Mattmann C., Rimoldi D., French L.E., Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388:190-195.
46. Micheau O., Thome M., Schneider P., Holler N., Tschopp J., Nicholson D.W., Briand C., Grutter M.G. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J. Biol. Chem. 2002, 277:45162-45171.
47. Kavuri S.M., Geserick P., Berg D., Dimitrova D.P., Feoktistova M., Siegmund D., Gollnick H., Neumann M., Wajant H., Leverkus M. Cellular FLICE-inhibitory protein (cFLIP) isoforms block CD95- and TRAIL death receptor-induced gene induction irrespective of processing of caspase-8 or cFLIP in the death-inducing signaling complex. J. Biol. Chem. 2011, 286:16631-16646.
48. Oberst A., Dillon C.P., Weinlich R., McCormick L.L., Fitzgerald P., Pop C., Hakem R., Salvesen G.S., Green D.R. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 2011, 471:363-367.
49. Ch'en I.L., Beisner D.R., Degterev A., Lynch C., Yuan J., Hoffmann A., Hedrick S.M. Antigen-mediated T cell expansion regulated by parallel pathways of death. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:17463-17468.
50. Bell B.D., Leverrier S., Weist B.M., Newton R.H., Arechiga A.F., Luhrs K.A., Morrissette N.S., Walsh C.M. FADD and caspase-8 control the outcome of autophagic signaling in proliferating T cells. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:16677-16682.
51. Lu J.V., Weist B.M., van Raam B.J., Marro B.S., Nguyen L.V., Srinivas P., Bell B.D., Luhrs K.A., Lane T.E., Salvesen G.S., Walsh C.M. Complementary roles of Fas-associated death domain (FADD) and receptor interacting protein kinase-3 (RIPK3) in T-cell homeostasis and antiviral immunity. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:15312-15317.
52. Ch'en I.L., Tsau J.S., Molkentin J.D., Komatsu M., Hedrick S.M. Mechanisms of necroptosis in T cells. J. Exp. Med. 2011, 208:633-641.
53. Bonnet M.C., Preukschat D., Welz P.S., van Loo G., Ermolaeva M.A., Bloch W., Haase I., Pasparakis M. The adaptor protein FADD protects epidermal keratinocytes from necroptosis in vivo and prevents skin inflammation. Immunity 2011, 35:572-582.
54. Gunther C., Martini E., Wittkopf N., Amann K., Weigmann B., Neumann H., Waldner M.J., Hedrick S.M., Tenzer S., Neurath M.F., Becker C. Caspase-8 regulates TNF-alpha-induced epithelial necroptosis and terminal ileitis. Nature 2011, 477:335-339.
55. Welz P.S., Wullaert A., Vlantis K., Kondylis V., Fernandez-Majada V., Ermolaeva M., Kirsch P., Sterner-Kock A., van Loo G., Pasparakis M. FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature 2011, 477:330-334.
56. Peter M.E. Programmed cell death: apoptosis meets necrosis. Nature 2011, 471:310-312.
57. Ch'en I.L., Tsau J.S., Molkentin J.D., Komatsu M., Hedrick S.M. Mechanisms of necroptosis in T cells. J. Exp. Med. 2011, 208:633-641.
58. Hitomi J., Christofferson D.E., Ng A., Yao J., Degterev A., Xavier R.J., Yuan J. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 2008, 135:1311-1323.
59. O'Donnell M.A., Perez-Jimenez E., Oberst A., Ng A., Massoumi R., Xavier R., Green D.R., Ting A.T. Caspase 8 inhibits programmed necrosis by processing CYLD. Nat. Cell Biol. 2011, 13:1437-1442.
60. Holler N., Zaru R., Micheau O., Thome M., Attinger A., Valitutti S., Bodmer J.L., Schneider P., Seed B., Tschopp J. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat. Immunol. 2000, 1:489-495.
61. He S., Wang L., Miao L., Wang T., Du F., Zhao L., Wang X. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 2009, 137:1100-1111.
62. Sun X., Yin J., Starovasnik M.A., Fairbrother W.J., Dixit V.M. Identification of a novel homotypic interaction motif required for the phosphorylation of receptor-interacting protein (RIP) by RIP3. J. Biol. Chem. 2002, 277:9505-9511.
63. Cho Y.S., Challa S., Moquin D., Genga R., Ray T.D., Guildford M., Chan F.K. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009, 137:1112-1123.
64. Degterev A., Hitomi J., Germscheid M., Ch'en I.L., Korkina O., Teng X., Abbott D., Cuny G.D., Yuan C., Wagner G., Hedrick S.M., Gerber S.A., Lugovskoy A., Yuan J. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat. Chem. Biol. 2008, 4:313-321.
65. Zhang D.W., Shao J., Lin J., Zhang N., Lu B.J., Lin S.C., Dong M.Q., Han J. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009, 325:332-336.
66. Vanlangenakker N., Vanden Berghe T., Vandenabeele P. Many stimuli pull the necrotic trigger, an overview. Cell Death Differ. 2012, 19:75-86.
67. Tenev T., Bianchi K., Darding M., Broemer M., Langlais C., Wallberg F., Zachariou A., Lopez J., MacFarlane M., Cain K., Meier P. The ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol. Cell 2011, 43:432-448.
68. Feoktistova M., Geserick P., Kellert B., Dimitrova D.P., Langlais C., Hupe M., Cain K., MacFarlane M., Hacker G., Leverkus M. cIAPs block ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol. Cell 2011, 43:449-463.
69. Upton J.W., Kaiser W.J., Mocarski E.S. Virus inhibition of RIP3-dependent necrosis. Cell Host Microbe 2010, 7:302-313.
70. Kepp O., Tesniere A., Schlemmer F., Michaud M., Senovilla L., Zitvogel L., Kroemer G. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 2009, 14:364-375.
71. Rosenbaum D.M., Degterev A., David J., Rosenbaum P.S., Roth S., Grotta J.C., Cuny G.D., Yuan J., Savitz S.I. Necroptosis, a novel form of caspase-independent cell death, contributes to neuronal damage in a retinal ischemia-reperfusion injury model. J. Neurosci. Res. 2010, 88:1569-1576.
72. Smith C.C., Davidson S.M., Lim S.Y., Simpkin J.C., Hothersall J.S., Yellon D.M. Necrostatin: a potentially novel cardioprotective agent?. Cardiovasc. Drugs Ther. 2007, 21:227-233.
73. Harper N., Farrow S.N., Kaptein A., Cohen G.M., MacFarlane M. Modulation of tumor necrosis factor apoptosis-inducing ligand-induced NF-kappa B activation by inhibition of apical caspases. J. Biol. Chem. 2001, 276:34743-34752.